Table 2. Psoriasis Severity at Baseline and 6-Month Follow-up by Treatment Group for PGA and PASI^a,b.

Severity Measurec	Medication	No. of Treatment Episodes	Outcomes		∆PGA/∆PASI	P Valued
			Baseline	6-mo Follow-up
Patients, No. (%)					NA
PGA 0/1	Methotrexate	115	0	41 (35.6)		.15
	Biologice	37	0	18 (48.6)
PASI75	Methotrexate	30	NA	12 (40.0)		.02
	Biologicf	28	NA	20 (71.4)
Severity scores, mean (SD)
PGA	Methotrexate	115	3.6 (0.7)	1.9 (1.1)	1.6 (1.2)	.32
	Biologice	37	3.6 (0.8)	1.8 (1.2)	1.9 (1.2)
PASI	Methotrexate	30	11.8 (6.2)	5.0 (5.1)	6.8 (4.7)	.02
	Biologicf	28	13.7 (7.7)	3.1 (2.4)	10.6 (7.4)

Abbreviations: PASI, Psoriasis Area and Severity Index; PASI75, 75% or greater improvement in PASI; PGA, Physician Global Assessment.

^aPatients could have been previously treated with conventional systemic agents except methotrexate. However, patients were treated at any 1 time with a single systemic medication.

^bParticipating sites provided PASI and/or PGA scores at medication initiation and during at least 1 follow-up visit. Patient numbers are therefore not identical in both groups.

^cPASI scores were determined using a range of 0 to 72, with the highest score indicating severe psoriasis, and/or PGA scores were determined using a scale of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe) at medication initiation.

^dContinuous (∆PGA and ∆PASI) and categorical (PGA 0/1 and PASI75) data were compared with generalized estimating equations to account for dependence of measurements with different systemic agents used at different times during the study period. The probability of methotrexate or biologic was estimated as a function of the characteristic.

^eEtanercept was the most frequently prescribed biologic (27 [73.0%]) followed by adalimumab (7 [18.9%]), ustekinumab (2 [5.4%]), and infliximab (1 [2.7%]).

^fEtanercept was the most frequently prescribed biologic (21 [75.0%]) followed by adalimumab (3 [10.7%]) and ustekinumab (4 [14.3%]).